MET and non-small cell lung carcinoma: However, a phase I study combining dacomitinib (a pan-HER inhibitor) with crizotinib (a small-molecule kinase inhibitor of MET and other RTKs) in advanced NSCLC patients showed limited success due to toxicity and modest tumor response [151].